Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab Vedotin + R-CHP in Previously Untreated DLBCL
NCT05406401Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Apr 2029
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Merck & Co.. Started Jul 2022; status: active, not recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05406401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406401.